IGM Biosciences News

Stifel Nicolaus Sticks to Its Buy Rating for IGM Biosciences (IGMS)

TipRanksApr 18 14:25 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: IGM Biosciences (IGMS) and Argenx Se (ARGX)

TipRanksApr 18 06:30 ET

IGM Biosciences Analyst Ratings

BenzingaApr 18 06:32 ET

Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Alpine Immune Sciences (ALPN) and IGM Biosciences (IGMS)

TipRanksMar 19 08:50 ET

IGM Biosciences Analyst Ratings

BenzingaMar 12 06:44 ET

IGM Biosciences: A Balanced Hold Rating Amid Financial Stability and Drug Development Risks

TipRanksMar 12 06:27 ET

IGM Biosciences Analyst Ratings

BenzingaMar 8 10:09 ET

Analysts Offer Insights on Healthcare Companies: Joint (JYNT), IGM Biosciences (IGMS) and Optinose (OPTN)

TipRanksMar 8 09:01 ET

Analysts' Top Healthcare Picks: Inventiva (IVA), IGM Biosciences (IGMS)

TipRanksMar 8 08:30 ET

RBC Capital Sticks to Their Buy Rating for IGM Biosciences (IGMS)

TipRanksMar 8 07:27 ET

IGM Biosciences Analyst Ratings

BenzingaFeb 9 10:31 ET

IGM Biosciences Shares Upgraded to Outperform on $1B+ Long-term Opportunity

InvestingFeb 9 08:58 ET

RBC Upgrades IGM Biosciences to Outperform From Sector Perform, Boosts Price Target to $21 From $9; Speculative Risk Kept

MT NewswiresFeb 9 07:33 ET

B of A Securities Downgrades IGM Biosciences to Neutral, Announces $8 Price Target

BenzingaDec 15, 2023 08:39 ET

IGM Biosciences Analyst Ratings

BenzingaDec 15, 2023 08:38 ET

HC Wainwright & Co. Downgrades IGM Biosciences to Neutral, Lowers Price Target to $7

BenzingaDec 7, 2023 11:10 ET

IGM Biosciences Analyst Ratings

BenzingaDec 7, 2023 11:07 ET

IGM Biosciences Analyst Ratings

BenzingaDec 6, 2023 10:49 ET

RBC Raises Price Target on IGM Biosciences to $9 From $8 on Reduced Ancillary Spend Amid Job Cuts, Keeps Sector Perform, Speculative Risk

MT NewswiresDec 6, 2023 07:59 ET

Morgan Stanley Adjusts IGM Biosciences Price Target to $8 From $15, Maintains Equal Weight Rating

MT NewswiresNov 15, 2023 09:07 ET